Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 7/20 | 0.53 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
| ▸ | PPARA | Q07869 | 6/20 | 0.46 |
| ▸ | PPARD | Q03181 | 5/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | IDE | P14735 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351386 | 0.93 | PPARG (0.50) | RORCPPARGPPARAPPARDPTGDR2 | |
| SCHEMBL351431 | 0.92 | RORC (0.49) | RORCPPARGPPARAPPARDPTGDR2 | |
| SCHEMBL350742 | 0.92 | RORC (0.51) | RORCPPARGPPARAPPARDPTGDR2 | |
| SCHEMBL351758 | 0.91 | RORC (0.54) | RORCPPARGPPARAPPARDHTR6 | |
| SCHEMBL352478 | 0.89 | RORC (0.57) | RORCPPARGPPARAPPARDPTGDR2 | |
| SCHEMBL350512 | 0.89 | PPARG (0.62) | RORCPPARGPPARAPPARDHTR6 | |
| SCHEMBL351583 | 0.89 | PPARG (0.46) | RORCPPARGPPARAPPARDPTGDR2 | |
| SCHEMBL349720 | 0.88 | PPARG (0.49) | RORCPPARGPPARAPPARDPTGDR2 | |
| SCHEMBL352424 | 0.88 | PPARG (0.44) | RORCPPARGPPARAPPARDPTGDR2 | |
| SCHEMBL350794 | 0.87 | PPARG (0.46) | RORCPPARGPPARAPPARDPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2012-01-19 | — | — | US | disclosed |
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2012-01-19 | — | — | US | disclosed |
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2012-01-19 | — | — | US | disclosed |
| US-8053463-B2 | e.g. {3-butoxy-5-[4-(4-trifluoromethoxy-phenoxy)-benzenesulfonyl]-phenyl}-acetic acid; peroxisome proliferator activated receptor modulator; antidiabetic agent; obesity, hyperlipidemia, dyslipidemia, hypertriglyceridemia, Syndrome X, insulin resistance, diabetic neuropathy, atherosclerosis, eczema | PLEXXIKON INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053463-B2 | e.g. {3-butoxy-5-[4-(4-trifluoromethoxy-phenoxy)-benzenesulfonyl]-phenyl}-acetic acid; peroxisome proliferator activated receptor modulator; antidiabetic agent; obesity, hyperlipidemia, dyslipidemia, hypertriglyceridemia, Syndrome X, insulin resistance, diabetic neuropathy, atherosclerosis, eczema | PLEXXIKON INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053463-B2 | e.g. {3-butoxy-5-[4-(4-trifluoromethoxy-phenoxy)-benzenesulfonyl]-phenyl}-acetic acid; peroxisome proliferator activated receptor modulator; antidiabetic agent; obesity, hyperlipidemia, dyslipidemia, hypertriglyceridemia, Syndrome X, insulin resistance, diabetic neuropathy, atherosclerosis, eczema | PLEXXIKON INC. (US) | 2011-11-08 | — | — | US | disclosed |
| EP-2114879-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080255201-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2008-10-16 | — | — | US | disclosed |
| US-20080255201-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2008-10-16 | — | — | US | disclosed |
| US-20080255201-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2008-10-16 | — | — | US | disclosed |
| WO-2008109700-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARA, PPARD | RORC 84/4885PPARG 1/4885PPARA 2/4885 |
| US-20080255201-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARA, PPARD | RORC 84/4885PPARG 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.